Starting from this background, in this study, we evaluated the in vitro efficacy of prexasertib mesylate monohydrate (hereafter referred to prexasertib), a novel Chk1/Chk2 inhibitor, in B- and T-progenitor ALL as single agent or in combination with different drugs like TKIs and other chemotherapy drugs like purine nucleoside analogue clofarabine. The gene discussed is CHEK2; the disease is acute lymphoblastic leukemia.